Promising clinical results for heavily pretreated patients with colorectal cancer
Patients with KRASG12C-mutant colorectal cancer treated with Adagrasib – a KRASG12C inhibitor that irreversibly and selectively binds KRASG12C, locking it, when in active state. In this MEDtalk Jared Weiss, oncologist, presents the promising results of adagrasib treatment
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.